HUTCHMED Employee Directory
Biotechnology ResearchHong Kong Island, Hong Kong501-1000 Employees
HUTCHMED is a biotechnology company focused on discovering and developing targeted therapies and immunotherapies for cancer and immunological diseases. As a commercial-stage organization, it has advanced ten cancer drug candidates from in-house discovery into clinical studies worldwide, and three oncology drugs have already been approved and launched. Headquartered in Hong Kong, the company pursues global development and commercialization of its medicines. Its work aims to provide new treatment options for patients and healthcare systems facing cancer and immune-related conditions, supported by an in-house discovery program and ongoing clinical programs. In June 2026, HUTCHMED reported Phase III results from the ESLIM-02 study of sovleplenib in warm antibody autoimmune hemolytic anemia, presented at the European Hematology Association Congress.